Rotavirus Chimeric Surface Proteins for Cryo-EM Structure Determination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining the structure of heterologous proteins and antigen-antibody complexes are limited by the constraints of X-ray crystallography, which is not suitable for high-throughput assays and requires significant resources, while traditional vaccine development faces challenges in genetic engineering and pathogen-derived antigen expression.
Innovation Solution
The use of rotavirus particles modified to display heterologous proteins via a two-part adapter system, allowing for rapid structure determination using cryo-electron microscopy and enabling the creation of immunogenic compositions for vaccine development without genetic modification of the rotavirus.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If X-ray crystallography is used to determine protein structure, then high-resolution structural information is obtained, but the method requires significant resources and is not suitable for high-throughput assays
Solution Approach 1:
The patent uses an adapter system consisting of two adapter polypeptides as an intermediary between the rotavirus VP7 surface protein and the heterologous protein. The first adapter polypeptide is fused to VP7, and the second adapter polypeptide is fused to the heterologous protein, enabling stable complex formation without direct genetic modification of the virus. This intermediary system allows rapid assembly of protein complexes for cryo-EM analysis, achieving high throughput while maintaining structural resolution.
2Ease of manufacture
If traditional vaccine development with genetic engineering is used, then pathogen-derived antigens can be expressed, but the process faces challenges in genetic engineering and requires significant time and resources
Solution Approach 1:
The patent segments the vaccine development process by separating the viral vector (rotavirus VP7) from the antigen of interest (heterologous protein). The adapter system allows independent expression and purification of each component, which then self-assemble into the final vaccine complex. This segmentation eliminates the need for complex genetic engineering of the virus itself, reducing development time and simplifying manufacturing.
Solution Approach 2:
The rotavirus VP7 surface protein modified with the first adapter polypeptide serves as a universal platform that can display multiple different heterologous proteins by simply changing the second adapter polypeptide fusion. This universal platform approach allows the same viral vector to be used for multiple different vaccine candidates, significantly reducing development time and resources across different vaccine programs.
Data Source
Figure 1A~1B
Figure 2
Figure 3A~3C
AI summary
The present invention relates to the use of rotavirus particles for displaying a heterologous protein, alone or in complex with another molecule. The invention further relates to methods that employ these modified rotavirus particles to rapidly determine the structure of the heterologous protein or the complex using cryo-electron microscopy (cryo-EM).The invention also relates to a method of immunising a patient, wherein said method comprises administering to the patient the modified rotavirus particles of the invention.